This content is machine translated Breast Cancer Locoregional therapy of the axilla: current recommendations at a glance Axillary dissection plays an important role in the treatment of breast carcinoma. It is able to reduce the rate of local recurrence and allows accurate staging, but is also associated… CME-Test
View Post 4 min This content is machine translated Pregnancy and multiple sclerosis Family planning with MS therapy need not be a challenge Multiple sclerosis (MS) predominantly affects women between the ages of 20 and 45 at the time of diagnosis – with an increasing incidence [1,2]. As a result, not only is…
View Post 4 min This content is machine translated Breast Cancer Metastatic pathways in focus Surgical or radiotherapeutic treatment of regional lymph nodes prolongs breast cancer survival and reduces the likelihood of distant metastasis. However, the effect on regional lymph node recurrence appears to be…
View Post 3 min This content is machine translated Ovarian cancer and the immune system The choice of chemotherapy is crucial Chemotherapy-induced changes in the immune system can be used therapeutically in the era of immuno-oncology. Accurate characterization of immunologic effects of different agents, in addition to better risk management, will…
View Post 3 min This content is machine translated Sponsored Content: HRD-positive advanced ovarian cancer. New option in first-line maintenance therapy Ovarian cancer is still the most lethal gynecologic tumor and, especially in advanced stages, the risk of progression remains high even with optimal therapy [1, 2]. Thus, effective treatments that…
View Post 4 min This content is machine translated Reflux Cases Heartburn during pregnancy – good advice is expensive A 32-year-old female patient with known GERD presents to her primary care physician’s office at 27 weeks’ gestation with increasing heartburn and regurgitation while lying down. She used to have…
View Post 2 min This content is machine translated Advanced high-grade serous ovarian cancer. HRD+ tumors: first PARP inhibitor approved for first-line maintenance therapy As the first and only PARP inhibitor, olaparib was recently approved by swissmedic for first-line maintenance therapy in patients with advanced, HRD-positive ovarian cancer. The addition of olaparib to bevacizumab resulted…
View Post 2 min This content is machine translated Hormone receptor-positive breast carcinoma New option for adjunctive therapy The GnRH agonist triptorelin has been used successfully for some time in various areas, including the treatment of hormone-dependent prostate cancer. The drug is now also approved for adjuvant therapy…
View Post 7 min This content is machine translated Triple-negative stage I-III breast carcinoma Attack on an untouchable While targeted therapies are on the rise, there are still tumors that cannot (yet) benefit from this development. One such is triple-negative breast carcinoma. But even here, far from targeted…
View Post 1 min This content is machine translated Interdisciplinary therapy management Gynecologist and oncologist talking about ovarian cancer Although the prognosis for ovarian cancer patients has improved in recent years, it is still the most lethal gynecologic tumor [1, 2]. In a video interview, gynecologist Prof. Andreas Günthert,…
View Post 6 min This content is machine translated Therapy of metastatic HER2-positive breast carcinoma Is a cure possible soon? In recent years, the prognosis of metastatic HER2-positive breast carcinoma has been significantly improved by the development of new agents such as the antibody-drug conjugate (ADC) trastuzumab-deruxtecan and the HER2-targeted…
